AR045007A1 - Compuestos de quinazolinona sustituidos con arilamina - Google Patents
Compuestos de quinazolinona sustituidos con arilaminaInfo
- Publication number
- AR045007A1 AR045007A1 ARP040102348A ARP040102348A AR045007A1 AR 045007 A1 AR045007 A1 AR 045007A1 AR P040102348 A ARP040102348 A AR P040102348A AR P040102348 A ARP040102348 A AR P040102348A AR 045007 A1 AR045007 A1 AR 045007A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- hydrogen
- cycloalkyl
- heteroaryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 108060003345 Adrenergic Receptor Proteins 0.000 abstract 2
- 102000017910 Adrenergic receptor Human genes 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- -1 cyano, hydroxy Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Compuestos representados mediante la fórmula (1), que son útiles en su condición de antagonistas de los adrenoceptores alfa-1 A/B, métodos de tratamiento de estados patológicos asociados con la actividad de los adrenoceptores alfa-1 A/B y métodos de obtención de dichos compuestos. Reivindicación 1: Un compuesto que tiene la fórmula (1), en la que: Y es alquileno C1-4 opcionalmente sustituido, alquenileno C2-4, heterociclileno o heterociclil-(alquileno C1-4); Z es -C(=O)- o -S(=O)2-; R y R' son alquilo; R5 se elige entre hidrógeno, halógeno, ciano, hidroxi, -R6 y -OR6; R6 se elige entre alquilo, alquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, cicloalquilo, cicloalquilo sustituido, heterociclo y heterociclo sustituido; R10 se elige entre hidrógeno, alquilo, alquilo sustituido, y heterociclo y cicloalquilo opcionalmente sustituido; Ar es arilo o heteroarilo opcionalmente sustituidos, con la condición de que si R5 es hidrógeno, entonces Y-Ar tomados juntos no sean i) bencilo sin sustituir, ii) bencilo que tenga un sustituyente en posición para elegido entre hidroxi y CO2H, o iii) bencilo que tenga un sustituyente hidroxi en posición meta; o un isómero o sal, hidrato o profármaco farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48457003P | 2003-07-02 | 2003-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045007A1 true AR045007A1 (es) | 2005-10-12 |
Family
ID=34062056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102348A AR045007A1 (es) | 2003-07-02 | 2004-07-02 | Compuestos de quinazolinona sustituidos con arilamina |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7244738B2 (es) |
| EP (1) | EP1644369A2 (es) |
| JP (1) | JP2009513502A (es) |
| KR (1) | KR100802856B1 (es) |
| CN (1) | CN1845924A (es) |
| AR (1) | AR045007A1 (es) |
| AU (1) | AU2004255581A1 (es) |
| BR (1) | BRPI0412285A (es) |
| CA (1) | CA2530312A1 (es) |
| MX (1) | MXPA05013905A (es) |
| RU (1) | RU2006102869A (es) |
| TW (1) | TW200519097A (es) |
| WO (1) | WO2005005395A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005005395A2 (en) * | 2003-07-02 | 2005-01-20 | F. Hoffmann-La Roche Ag | Arylamine-substituted quinazolinone compounds |
| CN1884262B (zh) * | 2005-06-24 | 2014-06-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 4-氨基哌啶类化合物及其医药用途 |
| WO2008041118A2 (en) * | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| WO2009026584A1 (en) * | 2007-08-23 | 2009-02-26 | Novelmed Therapeutics, Inc. | Methods of treating inflammatory conditions with adrenergic antagonists |
| US20110195974A1 (en) * | 2007-08-24 | 2011-08-11 | Rekha Bansal | Methods of treating inflammatory conditions with adrenergic antagonists |
| GB2454549B (en) * | 2007-09-25 | 2009-09-23 | Medical & Pharm Ind Tech & Dev | Uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an anti-allergic effect and histamine H1 receptor antagonism effect |
| EP2042179A1 (en) * | 2007-09-26 | 2009-04-01 | sanofi-aventis | Novel therapeutic uses of adrenergic alpha-1 receptor antagonists |
| US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
| US8512594B2 (en) | 2008-08-25 | 2013-08-20 | Air Products And Chemicals, Inc. | Curing agent of N,N′-dimethyl-meta-xylylenediamine and multifunctional amin(s) |
| US8501997B2 (en) * | 2008-08-25 | 2013-08-06 | Air Products And Chemicals, Inc. | Curing agent for low temperature cure applications |
| MX2011003168A (es) * | 2008-09-29 | 2011-05-19 | Gilead Sciences Inc | Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples. |
| CN103275017B (zh) * | 2013-05-30 | 2015-07-01 | 温州大学 | 一种2-取代喹唑啉酮化合物及其合成方法和用途 |
| KR102630720B1 (ko) | 2015-08-28 | 2024-01-29 | 세키스이 메디칼 가부시키가이샤 | 벤질 화합물 |
| CN108358856B (zh) * | 2018-01-08 | 2019-09-13 | 牡丹江医学院 | 一种防治消化性溃疡的药物以及其制备方法和用途 |
| CN108358903B (zh) * | 2018-04-24 | 2021-03-26 | 温州大学 | 2-取代杂环喹唑啉酮类化合物的合成方法 |
| DE102019114456B4 (de) * | 2019-05-29 | 2024-07-04 | Senorics Gmbh | Bispyranilidene, Dithiobispyranilidene und Diselenobispyranilidene und deren Verwendung |
| JPWO2023013757A1 (es) * | 2021-08-05 | 2023-02-09 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE792206A (es) * | 1971-12-02 | 1973-06-01 | Byk Gulden Lomberg Chem Fab | |
| US4442094A (en) * | 1980-12-23 | 1984-04-10 | Merck & Co., Inc. | (3-Aralkylamino-2-or-propoxy)heterocyclic compounds |
| US5084457A (en) | 1990-07-23 | 1992-01-28 | American Cyanamid Company | Benzoylaminoquinazolinones |
| MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
| DE4337609A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| US5756502A (en) | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
| US6376667B1 (en) * | 1997-11-26 | 2002-04-23 | Osi Pharmaceuticals, Inc. | Solid phase synthesis of heterocycles |
| IL137720A0 (en) | 1998-02-18 | 2001-10-31 | Neurosearch As | Compounds and their use as positive ampa receptor modulators |
| AU2826099A (en) | 1998-03-24 | 1999-10-18 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
| US6258819B1 (en) * | 1999-08-05 | 2001-07-10 | Syntex (U.S.A.) Llc | Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones |
| US6156758A (en) | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
| US20020082268A1 (en) | 2000-03-20 | 2002-06-27 | Yun Gao | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof |
| EP1276739A2 (en) | 2000-04-24 | 2003-01-22 | Bristol-Myers Squibb Company | Heterocycles that are inhibitors of impdh enzyme |
| WO2002024667A1 (en) | 2000-09-20 | 2002-03-28 | Merck Patent Gmbh | 4-amino-quinazolines |
| BR0116113A (pt) | 2000-12-12 | 2004-08-03 | Neurogen Corp | Espiro[isobenzofuran-1,4'-piperidin]-3-onas e 3h-espiroisoben-zofuran-1,4'-piperidinas |
| CA2432578C (en) * | 2001-01-02 | 2008-04-01 | F. Hoffmann-La Roche Ag | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
| WO2005005395A2 (en) * | 2003-07-02 | 2005-01-20 | F. Hoffmann-La Roche Ag | Arylamine-substituted quinazolinone compounds |
-
2004
- 2004-06-28 WO PCT/EP2004/006973 patent/WO2005005395A2/en not_active Ceased
- 2004-06-28 JP JP2006518045A patent/JP2009513502A/ja active Pending
- 2004-06-28 BR BRPI0412285-2A patent/BRPI0412285A/pt not_active IP Right Cessation
- 2004-06-28 MX MXPA05013905A patent/MXPA05013905A/es active IP Right Grant
- 2004-06-28 KR KR1020067000014A patent/KR100802856B1/ko not_active Expired - Fee Related
- 2004-06-28 CA CA002530312A patent/CA2530312A1/en not_active Abandoned
- 2004-06-28 RU RU2006102869/04A patent/RU2006102869A/ru not_active Application Discontinuation
- 2004-06-28 EP EP04740373A patent/EP1644369A2/en not_active Withdrawn
- 2004-06-28 AU AU2004255581A patent/AU2004255581A1/en not_active Abandoned
- 2004-06-28 CN CNA2004800250340A patent/CN1845924A/zh active Pending
- 2004-07-01 TW TW093119909A patent/TW200519097A/zh unknown
- 2004-07-02 US US10/884,768 patent/US7244738B2/en not_active Expired - Fee Related
- 2004-07-02 AR ARP040102348A patent/AR045007A1/es unknown
-
2007
- 2007-06-22 US US11/821,493 patent/US20070265446A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1644369A2 (en) | 2006-04-12 |
| KR100802856B1 (ko) | 2008-02-12 |
| KR20060031675A (ko) | 2006-04-12 |
| CA2530312A1 (en) | 2005-01-20 |
| MXPA05013905A (es) | 2006-02-24 |
| US20070265446A1 (en) | 2007-11-15 |
| JP2009513502A (ja) | 2009-04-02 |
| TW200519097A (en) | 2005-06-16 |
| WO2005005395A2 (en) | 2005-01-20 |
| US7244738B2 (en) | 2007-07-17 |
| US20050038016A1 (en) | 2005-02-17 |
| BRPI0412285A (pt) | 2006-09-19 |
| WO2005005395A3 (en) | 2005-05-06 |
| RU2006102869A (ru) | 2007-08-10 |
| CN1845924A (zh) | 2006-10-11 |
| AU2004255581A1 (en) | 2005-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045007A1 (es) | Compuestos de quinazolinona sustituidos con arilamina | |
| CR7950A (es) | Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas | |
| AR049446A1 (es) | Preparacion de pregabalina ((s)-(+)-aminometil-5-metilhexanoico) y compuestos relacionados | |
| EP1829858A3 (en) | Dibenzylamine compounds and pharmaceutical use thereof | |
| ATE556058T1 (de) | 1-(2h)-isochinolonderivat | |
| JP2004131511A5 (es) | ||
| AR090649A2 (es) | Inhibidores del virus de la hepatitis c | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| DK1063228T5 (da) | Cycloalkenderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| EA200601830A1 (ru) | Ортозамещённые арильные или гетероарильные амидные соединения | |
| BR0315405A (pt) | Compostos inibidores da integrase tricìclica pré-organizados | |
| ES2196772T3 (es) | Compuestos amino ciclicos. | |
| CO4910135A1 (es) | Derivados cetolidos 6-0 sustituidos de la eritromicina que tienen actividad bacteriana | |
| MA32642B1 (fr) | Amides utiles en therapie | |
| TNSN07178A1 (fr) | N-sulfonylaminobenzyl-2-phenoxy-acetamides substitues | |
| AR043055A1 (es) | Derivados de 1-(4-benzil-piperazin-1-il)-3- fenil-propenona | |
| CO4980859A1 (es) | Arilpiperazinas que tienen actividad sobre el receptor 1a de la serotonina | |
| CA2539349A1 (en) | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | |
| SV2002000244A (es) | Metodos y compuestos para inhibir mrp1 ref.x-13353 | |
| DE602004020730D1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
| CO4700291A1 (es) | Compuestos quimicos | |
| EA200000484A1 (ru) | Способ получения производных тиазолидиндиона | |
| CA2531064A1 (en) | Novel heteroaryl derivative | |
| RU96101173A (ru) | Производные пиридазинонов | |
| EP1707564A3 (fr) | Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |